The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...